Certified by Founder Lodge
R1 Therapeutics
United States - Redwood City, California
START UP
1 Disclosed Funding Rounds $77,500,000
0 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
R1 Therapeutics is developing category-defining, first-in-class therapies for patients with kidney disease, starting with lead asset AP306 for the treatment of hyperphosphatemia in patients w
| Date | Round | Raised | Participating Investors |
|---|---|---|---|
| March, 18 ,2026 | Series A | $77,500,000 |
F-Prime Capital
Abingworth
DaVita Venture Group
SymBiosis(US)
Carmot Therapeutics, Inc.
Ozette Technologies
NAPIGEN, INC.
TrueBinding
Loopworm
Quorus | $5,000,000 | (Mar 18, 2026)
Turquoise(US) | $40,000,000 | (Mar 18, 2026)
Conduit Health | $17,000,000 | (Mar 18, 2026)
iDEL Therapeutics GmbH | $10,381,635 | (Mar 18, 2026)
